Soyeon Yoo

Prof. Dr. Soyeon Yoo

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JBJisun Bang
Jisun Bang
SLSang Ah Lee
Sang Ah Lee
GKGwanpyo Koh
Gwanpyo Koh
SYSoyeon Yoo
Soyeon Yoo
There is a growing interest in the role of glucagon in type 2 diabetes mellitus (T2DM). Glucagon and insulin regulate glucose and lipid metabolism. Metabolic syndrome is an important risk factor for cardiovascular disease in patients with T2DM. We investigated the association between glucagon to insulin ratio and metabolic syndrome in patients with T2DM. This is a cross-sectional study involving 317 people with type 2 diabetes. Glucagon and insulin levels were measured in a fasted state and 30 min after ingesting a standard mixed meal. The Criteria of the International Diabetes Federation defined metabolic syndrome. Two hundred nineteen (69%) of the subjects had metabolic syndrome. The fasting glucagon to insulin ratio was significantly lower in patients with metabolic syndrome (14.0 ± 9.7 vs. 17.3 ± 10.3, p < 0.05). The fasting glucagon to insulin ratio was significantly lowered as the number of metabolic syndrome components increased. In hierarchical logistic regression analysis, the fasting glucagon to insulin ratio significantly contributed to metabolic syndrome even after adjusting for other covariates. The fasting glucagon to insulin ratio is inversely associated with metabolic syndrome in patients with type 2 diabetes. This suggests that glucagon-targeted therapeutics may reduce cardiovascular risk by improving metabolic syndrome.

1 June 2020 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
SYSoyeon Yoo
Soyeon Yoo
JBJu Young Bae
Ju Young Bae
JMJaecheol Moon
Jaecheol Moon
GKGwanpyo Koh
Gwanpyo Koh

13 October 2017 in Endocrine Research
Verified
Journal Article
Closed access
SYSoyeon Yoo
Soyeon Yoo
EYEun-Jin Yang
Eun-Jin Yang
SLSang Ah Lee
Sang Ah Lee
GKGwanpyo Koh
Gwanpyo Koh
Purpose: Metabolic syndrome increases the risk of cardiovascular disease. Recently glucagon-like peptide 1 (GLP-1) agonists proved to be effective in preventing cardiovascular disease (CVD) in patients with type 2 diabetes. We investigated the association of blood incretin levels with metabolic syndrome in patients with type 2 diabetes. Materials and methods: This is a cross-sectional study involving 334 people with type 2 diabetes. Intact GLP-1 (iGLP-1) and intact glucose-dependent insulinotropic polypeptide (iGIP) levels were measured in a fasted state and 30 min after ingestion of a standard mixed meal. Metabolic syndrome was diagnosed based on the criteria of the International Diabetes Federation. Results: Two hundred twenty-five (69%) of the subjects have metabolic syndrome. The fasting iGLP-1 level was no different between groups. Thirty-min postprandial iGLP-1 was non-significantly lower in the subjects who had metabolic syndrome. Incremental iGLP-1 (ΔiGLP-1, the difference between 30-min postmeal and fasting iGLP-1 levels) was significantly lower in those with metabolic syndrome. There were no significant differences in fasting iGIP, postprandial iGIP, and ΔiGIP between groups. The ΔiGLP-1, but not ΔiGIP levels decreased significantly as the number of metabolic syndrome components increased. In hierarchical logistic regression analysis, the ΔiGLP-1 level was found to be a significant contributor to metabolic syndrome even after adjusting for other covariates. Conclusion: Taken together, the iGLP-1 increment in the 30 min after meal ingestion is inversely associated with metabolic syndrome in patients with type 2 diabetes. This suggests that postmeal iGLP-1 increment could be useful in assessing cardiovascular risk in type 2 diabetes.

Verified
Journal Article
Open access
PDF file
SYSoyeon Yoo
Soyeon Yoo
DKDongkyu Kim
Dongkyu Kim
GKGwanpyo Koh
Gwanpyo Koh
Background: We aimed to investigate the changes in glucagon levels in people with diabetes after the ingestion of a mixed meal and the correlations of variation in glucagon levels with incretin and clinico-biochemical characteristics. Methods: Glucose, C-peptide, glucagon, intact glucagon-like peptide 1 (iGLP-1), and intact glucose-dependent insulinotropic polypeptide (iGIP) were measured in blood samples collected from 317 people with diabetes before and 30 min after the ingestion of a standard mixed meal. The delta (Δ) is the 30-min value minus the basal value. Results: At 30 min after meal ingestion, the glucagon level showed no difference relative to the basal value, whereas glucose, C-peptide, iGLP-1, and iGIP levels showed a significant increase. In univariate analysis, Δglucagon showed not only a strong correlation with HbA1c but also a significant correlation with fasting glucose, Δglucose, and estimated glomerular filtration rate. However, Δglucagon showed no significant correlations with ΔiGLP-1 and ΔiGIP. In the hierarchical multiple regression analysis, HbA1c was the only variable that continued to show the most significant correlation with Δglucagon. Conclusions: People with diabetes showed no suppression of glucagon secretion after meal ingestion. Patients with poorer glycemic control may show greater increase in postprandial glucagon level, and this does not appear to be mediated by incretin.

1 January 2019 in Diabetes & Metabolism Journal
Verified
Journal Article
Open access
PDF file
SYSoyeon Yoo
Soyeon Yoo
EYEun-Jin Yang
Eun-Jin Yang
GKGwanpyo Koh
Gwanpyo Koh
Yoo S, et al. Diabetes Metab J. 2019 Jan;43:e8. https://doi.org/10.4093/dmj.2018.0105

25 September 2026 in JCEM Case Reports
Verified
Journal Article
Open access
SCSoon Young Choi
Soon Young Choi
HCHyounjung Chin
Hyounjung Chin
SYSoyeon Yoo
Soyeon Yoo
SLSang Ah Lee
Sang Ah Lee
GKGwanpyo Koh
Gwanpyo Koh
A 77-year-old woman presented with worsening glycemic control and hypokalemia and was found to have adrenocorticotropic hormone (ACTH)-dependent hypercortisolism with loss of diurnal cortisol variation and failure of suppression on low- and high-dose dexamethasone suppression tests. Computed tomography (CT) demonstrated bilateral adrenal enlargement, whereas pituitary magnetic resonance imaging and chest CT failed to identify a source of ACTH secretion, leading to a diagnosis of occult ectopic ACTH syndrome. During 15 years of follow-up, she exhibited cyclic fluctuations in ACTH and cortisol concentrations, including episodes of severe hypercortisolism with ACTH levels exceeding 2000 pg/mL (>440 pmol/L) (reference range, 7.2-63.6 pg/mL [1.6-14.0 pmol/L]) and cortisol concentrations of 30-60 μg/dL (828-1656 nmol/L) (reference range, 6.2-19.4 μg/dL [171-535 nmol/L]), alternating with spontaneous remission. Serial imaging revealed dynamic adrenal morphological changes, with enlargement during hypercortisolemic phases and regression during remission. During treatment with ketoconazole, mitotane, and osilodrostat, the patient experienced recurrent significant hypocortisolic episodes, some of which were likely treatment-associated and required hydrocortisone replacement therapy. This case highlights an exceptionally prolonged course of cyclic ectopic ACTH syndrome characterized by extreme hormonal oscillation, reversible adrenal hyperplasia, and recurrent hypocortisolism, emphasizing the importance of long-term biochemical surveillance and individualized therapeutic adjustment.